IGHE and immunoglobulin G4-related sclerosing disease: This is supported by findings in a recent retrospective cohort study of predictors of disease relapse in IgG4-RD after rituximab therapy; in 21 (37%) patients experiencing disease relapse, baseline serum IgG4, IgE, and circulating eosinophils predicted relapse.18